Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. Octapharma employs more than 11,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Immunotherapy, Haematology, and Critical Care. Octapharma has seven R&D sites and five state-of-the-art manufacturing facilities in Austria, France, Germany and Sweden, and operates more than 190 plasma donation centres across Europe and the US. Check our community guidelines: https://bit.ly/3M8ioml
Location: Switzerland, Schwyz, Lachen
Employees: 10001+
Founded date: 1983
Mentions in press and media 17
| Date | Title | Description |
| 30.07.2026 | Octapharma selects York County for its first US manufacturing site | COLUMBIA, S.C. — The South Carolina Department of Commerce (S.C. Commerce) today announced the completion of final approvals for Octapharma’s first U.S. manufacturing and production facility in York County. The $1.5 billion investment is pr... |
| 29.07.2026 | News from our Partners: Octapharma selects York County for its first US manufacturing site | COLUMBIA, S.C. — The South Carolina Department of Commerce (S.C. Commerce) today announced the completion of final approvals for Octapharma’s first U.S. manufacturing and production facility in York County. The $1.5 billion investment is pr... |
| 17.04.2026 | World Hemophilia Day 2026 - April 17, 2026 - "Diagnosis: First step to care." | MONTREAL, April 17, 2026 /PRNewswire/ -- On April 17, 2026, the global inherited bleeding disorders community will come together on World Hemophilia Day to advocate for all inherited bleeding disorders. This year's theme of "Diagnosis:... |
| 26.02.2026 | Abram Scientific Fuels CoagCare with $11.75 Million Series A for Rapid Diagnostics | Abram Scientific secured $11.75 million in Series A funding. This investment propels CoagCare, their portable coagulation diagnostics platform. CoagCare rapidly identifies blood clotting and bleeding disorders. It aims to revolutionize pati... |
| 25.02.2026 | Abram Scientific Raises $11.75M in Series A Funding | Abram Scientific, a Menlo Park, CA-based medical device company, raised $11.75M in Series A funding. The round was led by Octapharma AG, with participation from existing and new investors affiliated with University of Colorado Anschutz. The... |
| 25.02.2026 | Abram Scientific: $11.75 Million Series A Raised For Portable Coagulation Diagnostics Platform CoagCare | Abram Scientific announced it has secured $11.75 million in Series A financing to accelerate development of its proprietary portable coagulation diagnostics platform, CoagCare. The round was led by global pharmaceutical company Octapharma A... |
| 17.04.2025 | World Hemophilia Day 2025 - April 17, 2025 - "Access for all: Women and girls bleed too" | MONTREAL, April 17, 2025 /PRNewswire/ -- On April 17, 2025, the global bleeding disorders community will come together under the theme "Access for all: Women and girls bleed too" and celebrate World Hemophilia Day. Today, women an... |
| 13.08.2024 | Octapharma USA: JAMA Network Open Publishes Study Results Demonstrating Efficacy & Safety of Balfaxar® For Warfarin Reversal in Urgent Surgery & Invasive Procedures | PARAMUS, N.J., Aug. 13, 2024 /PRNewswire/ -- Octapharma USA announced the results from the Phase III (LEX-209) study on the efficacy and safety of Balfaxar® (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octa... |
| 09.08.2024 | FDA Roundup: August 9, 2024 | SILVER SPRING, Md., Aug. 9, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA invites the public to register for the public meeting on the De... |
| 10.06.2024 | Octapharma's continuing dedication to improving the lives of people with rare bleeding disorders to be showcased at ISTH 2024 | Octapharma to present new clinical and scientific findings for wilate® and Nuwiq® at the upcoming ISTH 2024 Congress New data and clinical study developments to be showcased in seven oral presentations, two posters and two Supported Symposi... |
Show more